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Abstract
Bladder carcinogenesis is believed to follow two alternative pathways driven by the loss of chromosome 9 and the gain of
chromosome 7, albeit other nonrandom copy number alterations (CNAs) were identified. However, confirmation studies are
needed since many aspects of this model remain unclear and considerable heterogeneity among cases has emerged. One of
the purposes of this study was to evaluate the performance of a targeted test (UroVysion assay) widely used for the
detection of Transitional Cell Carcinoma (TCC) of the bladder, in two different types of material derived from the same
tumor. We compared the results of UroVysion test performed on Freshly Isolated interphasic Nuclei (FIN) and on Formalin
Fixed Paraffin Embedded (FFPE) tissues from 22 TCCs and we didn’t find substantial differences. A second goal was to assess
the concordance between array-CGH profiles and the targeted chromosomal profiles of UroVysion assay on an additional
set of 10 TCCs, in order to evaluate whether UroVysion is an adequately sensitive method for the identification of selected
aneuploidies and nonrandom CNAs in TCCs. Our results confirmed the importance of global genomic screening methods,
that is array based CGH, to comprehensively determine the genomic profiles of large series of TCCs tumors. However, this
technique has yet some limitations, such as not being able to detect low level mosaicism, or not detecting any change in
the number of copies for a kind of compensatory effect due to the presence of high cellular heterogeneity. Thus, it is still
advisable to use complementary techniques such as array-CGH and FISH, as the former is able to detect alterations at the
genome level not excluding any chromosome, but the latter is able to maintain the individual data at the level of single
cells, even if it focuses on few genomic regions.
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Introduction
Bladder cancer is the seventh most common cancer worldwide
[1] and the fourth most common cancer diagnosed in men in the
USA and European countries [2]. Transitional Cell Carcinoma
(TCC) comprises the majority of bladder cancers accounting for
more than 90%. At presentation, the majority (,70%) are
superficial, exophytic, papillary tumors that are well-differentiated
(low-grade, LG) and do not penetrate the epithelial basement
membrane (stage Ta) [1,3]; the remaining are muscle invasive
(T2–T4) or microinvasive tumors (T1), that have penetrated the
lamina propria but are not invading the muscle. In this minority,
the tumor epithelium is poorly differentiated (high-grade, HG) and
often associated with carcinoma in situ (CIS), which despite its
superficiality is composed of poorly differentiated epithelium. This
is thought to be representative of a precursor lesion [1]. Prognosis
for LG Ta tumors is generally good because such tumors rarely
progress, but monitoring is necessary given the significant risk of
recurrence (up to 70%) [4]; this is necessary also for HG Ta
(TaG3) and T1 tumors that represent a high risk of progression to
muscle invasion. For patients with muscle invasive tumors ($T2),
metastasis is a major clinical problem and cystectomies are usually
indicated. Prognosis is relatively poor with only 50% survival at 5
years since diagnosis [4].
The biological differences among these groups probably reflects
the underlying genetic heterogeneity which leads to specific
pathways of tumor development and progression. Innumerable
studies have traced the status of known oncogenes and tumor
suppressor genes and have revealed several recurring chromo-
somal changes associated with the pathologic stage and/or
outcome of the tumor [5,6]. Moreover, based on the well known
genetic alterations of bladder cancer, a multi-target fluorescence in
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UroVysion FISH detection system, approved by the U.S. Food
and Drug Administration, is based on three centromeric probes for
chromosomes 3, 7 and 17 and a fourth probe to the 9p21 region,
for the detection of chromosomal aneusomy and/or deletion of
9p21 locus, which are common genetic alterations in TCCs [8,9].
UroVysion has been initially used in the last decade only for the
surveillance, but recently also as a bladder cancer screening tool in
patients with hematuria [10–12]. However, other methods have
been applied to detect copy number changes associated with
tumor development and progression of TCC. Conventional
comparative genomic hybridization (CGH) studies have provided
a great deal of information, including the identification of a
number of genomic regions of DNA amplification containing
known or candidate oncogenes [13–15]. On the other hand, the
location of tumor suppressor genes in TCC have largely been
identified by loss of heterozygosity (LOH) analysis [16]. With the
use of the high-resolution mapping of array-based CGH, novel
copy number alterations (CNAs) were identified in many small
genomic regions that were not detected in previous studies [17–
19]. The data collected so far, in addition to the identification of at
least two cytogenetic pathways for tumor development, i.e. the loss
of chromosome 9 and the gain of chromosome 7 [20–22], may be
helpful in designing new individualized therapies. However
confirmation studies are needed since many aspects of this model
remain unclear, in particular on the chronological order of the
aberrations during the disease progression. For a sensible
identification of the genes underlying the chromosomal abnor-
malities, it becomes crucial to use reliable techniques and to go
through the data validation process. This issue was recently
addressed for prostate and breast cancer, gliomas and multiple
myeloma [23–27], but not for bladder cancer. Although Formalin
Fixed Paraffin Embedded (FFPE) specimens has several advan-
tages, such as the certainty of histological diagnosis and allow
retrospective studies of a large number of samples, fresh tissues are
considered the most reliable for molecular genetic analysis; they
provide a comprehensive analysis of the biopsy, although the
material does not have a histological diagnosis.
The first goal of this study was to evaluate the performance of a
targeted test intwo different types ofmaterial derived from the same
tumor. In the first step we compared the results of UroVysion test
performed on Freshly Isolated interphasic Nuclei (FIN) and on
FFPE tissues from 22 TCCs (Figure 1). Furthermore, a second goal
was to assess the concordance between array-CGH profiles and the
targeted chromosomal profiles, in order to evaluate whether
UroVysion is an adequately sensitive method for the identification
of selected aneuploidies and nonrandom CNAs in TCCs. The
second step of comparison was applied on an additional set of 10
TCCs, between data derived from either array-CGH on FIN and
from UroVysion analysis on FFPE tissues (Figure 1).
Results
First Step of analysis: comparison between UroVysion
data from FIN and FFPE
TCC can be distinguished in high or low grade (HG or LG) and
in muscle invasive or not (IN or NI). In the first step of analysis 22
TCCs (9 LGNI, 1 LGIN, 3 HGNI, 9 HGIN) were analyzed by
UroVysion test applied in duplicate from the same biopsy on
FFPE and FIN samples (Figure 1).
In the analysis based on the multinomial model, FIN data were
generally comparable to those extracted from FFPE counterpart in
LGNI group, in terms of percentages of loss, disomy and gain
(Table 1; for a detailed list see Table S2). By contrast, in HGNI
group the two types of analysis generated concordant results only
for CEP 3 (Chromosome Enumeration Probe 3). Indeed in CEP 7
and CEP17, FIN tended to detect a lower percentage of both loss
(1,7 vs 10 for CEP 7; 6 vs 11,3 for CEP17) and disomy (42,7 vs
Figure 1. Methodological approach of this study. The two step strategy of analysis applied in this study.
doi:10.1371/journal.pone.0024237.g001
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percentage of gain was reported (55,7 vs 27,7 for CEP7; 45,7 vs 28
for CEP 17). Finally, for Locus Specific Identifier (LSI) 9p21 FIN
tended to detect a higher percentage of both disomy (58,3 vs 20,0)
and gain (10,3 vs 8,7) but a lower percentage of loss (31,3 vs 71,3).
On the other hand, in HGIN group the two types of analysis
generated discordant results only for CEP 3: FIN tended to detect
a higher percentage of loss (14,9 vs 2,2) and a lower percentage of
gain (48,1 vs 62,5) than FFPE.
These results were confirmed in the more refined analysis by a
Poisson model (Figure 2). In LGNI group, the average number of
signals for CEP3, CEP7, CEP17 and for the 9p21 region was 2.3,
1.8, 2.0, 0.5 (in FIN samples) and 2.4, 2.1, 2.2, 0.9 (in FFPE) with
no significant difference between the two types of test (Figure 2, A).
On the other hand, in HGNI group the average number of signals
for CEP3, CEP7, CEP17 and for the 9p21 region was 2.5, 2.9, 2.7,
1.8 (in FIN samples) and 2.3, 2.3, 2.3, 1.2 (in FFPE) with
statistically significant differences between the two tests except for
CEP3 (Figure 2, B). Conversely, in HGIN group, the average
number of signals for CEP3, CEP7, CEP17 and for the 9p21
region was 2.5, 2.7, 2.3, 1.2 (in FIN) and 3.0, 2.7, 2.7, 1.2 (in FFPE
samples), with significant difference for CEP3 (Figure 2, C).
Genomic copy number alterations (CNAs) in freshly
isolated nuclei (FIN) by array-CGH
In the second step of our analysis we first performed array-CGH
on an additional set of 10 TCCs (6 HGIN, 1 HGNI, 3 LGNI), in
order to detect CNAs between tumor and reference DNA. The most
frequent CNAs are summarized in Table 2 (detailed form in Table
S3). We classified the samples into two categories: infiltrating tumors
(IN-TCCs: 70CR09, 81CR09, 04CR10, 09CR10, 10CR10,
26CR10) and non infiltrating tumors (NI-TCCs: 28CR09,
75CR09, 80CR09, 82CR09) (Figure 3). In general, as expected,
IN-TCCs have many more CNAs than NI-TCCs. 20q gain was
shared by 4/6 IN-TCC tumors, while 2/4 NI-TCCs; 3p25.2 and
17q21 gains by 4/6 IN-TCC tumors and 1/4 NI-TCCs; 5p and 20p
gain by 3/6 IN-TCC and 2/4 NI-TCCs; 6p22.3 and 11q13 was
shared only by IN-TCC (3/6 and 2/6 respectively); finally 3q and 8q
were in 1/6 IN-TCCs and 1/4 NI-TCCs. For the losses: 9p and
9p21werein4/6and3/6IN-TCCswhilein2/4and3/4NI-TCCs;
Table 1. Percentages of loss, disomy, gain by type of tumor, probe analyzed and test applied.
LG NI
Probe Test % loss (95% CI) % diso (95% CI) % gain (95% CI) p-value
CEP 3 FIN 13,2 (6,7 ; 24,3) 57,9 (32,2 ; 79,9) 28,9 (23,5 ; 35,0) 0,520
FFPE 10,0 (4,2 ; 22,1) 55,0 (35,2 ; 73,3) 35,0 (30,5 ; 39,7)
CEP 7 FIN 28,0 (14,6 ; 47,0) 57,8 (35,6 ; 77,2) 14,2 (13,1 ; 15,4) 0,134
FFPE 10,4 (5,0 ; 20,6) 70,2 (57,2 ; 80,6) 19,3 (17,6 ; 21,1)
CEP 17 FIN 14,4 (9,2 ; 21,7) 71,3 (56,7 ; 82,5) 14,4 (12,7 ; 16,1) 0,133
FFPE 9,1 (5,1 ; 15,7) 68,9 (50,9 ; 82,5) 22,0 (18,9 ; 25,5)
LSI 9p21 FIN 84,9 (53,6 ; 96,5) 14,5 (3,2 ; 46,6) 0,6 (0,6 ; 0,6) 0,323
FFPE 73,2 (55,1 ; 85,9) 24,0 (10,9 ; 45,0) 2,8 (2,7 ; 2,8)
HG NI
Probe Test % loss (95% CI) % diso (95% CI) % gain (95% CI) p-value
CEP 3 FIN 5,3 (1,2 ; 20,7) 48,0 (16,6 ; 81,0) 46,7 (32,9 ; 61,0) 0,307
FFPE 11,7 (5,5 ; 23,0) 56,3 (33,3 ; 77,0) 32,0 (27,3 ; 37,1)
CEP 7 FIN 1,7 (0,5 ; 5,2) 42,7 (16,5 ; 73,8) 55,7 (38,6 ; 71,5) ,0.001*
FFPE 10,0 (4,9 ; 19,4) 62,3 (31,6 ; 85,6) 27,7 (21,7 ; 34,6)
CEP 17 FIN 6,0 (3,0 ; 11,5) 48,3 (13,7 ; 84,7) 45,7 (28,3 ; 64,2) 0,020*
FFPE 11,3 (5,8 ; 21,1) 60,7 (24,3 ; 88,1) 28,0 (20,3 ; 37,3)
LSI 9p21 FIN 31,3 (18,0 ; 48,7) 58,3 (30,1 ; 82,0) 10,3 (8,7 ; 12,2) ,0.001*
FFPE 71,3 (56,3 ; 82,8) 20,0 (6,8 ; 46,2) 8,7 (8,0 ; 9,4)
HG IN
Probe Test % loss (95% CI) % diso (95% CI) % gain (95% CI) p-value
CEP 3 FIN 14,9 (7,2 ; 28,4) 36,9 (22,0 ; 54,9) 48,1 (44,2 ; 52,1) 0,038*
FFPE 2,2 (0,7 ; 6,9) 35,3 (24,0 ; 48,5) 62,5 (55,0 ; 9,4)
CEP 7 FIN 8,9 (5,0 ; 15,6) 50,9 (29,6 ; 72,0) 40,1 (32,7 ; 48,1) 0,741
FFPE 3,6 (1,5 ; 8,5) 54,0 (36,7 ; 70,4) 42,4 (35,7 ; 49,3)
CEP 17 FIN 18,5 (9,0 ; 34,3) 49,9 (23,4 ; 76,4) 31,6 (25,4 ; 38,5) 0,244
FFPE 6,9 (2,7 ; 16,8) 47,5 (27,0 ; 69,0) 45,5 (37,6 ; 53,7)
LSI 9p21 FIN 63,3 (40,2 ; 81,6) 20,9 (2,5 ; 73,3) 15,7 (13,1 ; 18,8) 0,934
FFPE 64,5 (39,2 ; 83,6) 20,0 (2,4 ; 71,5) 15,5 (13,5 ; 17,8)
p-values refer to the comparison between the two type of analysis obtained by a multinomial model with 95% confidence interval.
doi:10.1371/journal.pone.0024237.t001
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in 3/6 IN-TCCs and 1/4 NI-TCCs; 8p loss only in 2/6 IN-TCCs.
To identify possible enrichment of functional groups in the
genes within regions with gain and loss of HGIN and LGNI
tumors, a gene ontology annotation analysis was performed using
the GOstat software. For HGIN emerged a statistically significant
under-representation (p,0.05) of genes involved in cell differen-
tiation, in cell cycle and in positive regulation of apoptosis and
programmed cell death; in addition a statistically significant over-
representation of genes involved in cell proliferation and in
regulation of apoptosis. On the other hand the analysis evidenced
for LGNI tumors a statistically significant under-representation of
genes involved in induction of apoptosis and programmed cell
death (Table S4).
Second Step of analysis: comparison between array-CGH
profiles on FIN and UroVysion data on FFPE
We next performed FISH analysis by means of Urovysion test
on the additional set of 10 TCCs analyzed by array-CGH; when
possible, two tumoral areas of the same section were scored in
order to increase the number of cell analyzed and to have data as
representative as possible, given the well-known heterogeneity in
this type of cancer. For each probe a statistical analysis was
performed to verify that the signal counts on 100 cells were
different considering the two areas separately or mixing them
together. Concordant results between the two tumoral areas were
reported in two HGIN cases (070CR09 and 081CR09) (Figure 4,
A); conversely, statistically significant contrasting results (p, 0.05)
were reported in two HGIN cases (009CR10 and 026CR10)
(Figure 4, B); in the remaining six cases statistically significant
differences between the two tumoral areas were evidenced for one
(010CR10), two (028CR09 and 080CR09) or three probes
(004CR10) (see also Table S5). These data stressed the overall
high intra-tumor heterogeneity of these samples.
Then, we made an attempt to compare the UroVysion data on
FFPE just reported with the array-CGH profiles from the 10
TCCs, described above. For this purpose for each sample we
extrapolated the results for array-CGH analysis corresponding to
the four UroVysion targeted chromosomes and compared them
with FISH data (Table 3). Full concordance was found only for
Figure 2. Statistical analysis by a Poisson model. Estimated count of signals observed in each probe (with 95% confidence interval) obtained in
each type of tumor, accounting for clustering. The reported p-values refer to the comparison between FFPE and FIN methods. Panel A= LGNI (9 pts);
panel B= HGNI (3 pts); panel C= HGIN (9 pts).
doi:10.1371/journal.pone.0024237.g002
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LGNI HGNI HGIN
GAIN ref 75CR09 80CR09 82CR09 28CR09 04CR10 09CR10 10CR10 26CR10 70CR09 81CR09
3p25 18 ++ ++ +
3q 18,19 ++
5p 18,19 ++ ++ +
6p22.3 18,19 ++ +
8q 18,19 ++
11q13 18 ++
17q21 18 ++++ +
20p 18,19 ++ + + +
20q 18,19 + + ++++
LOSS ref 75CR09 80CR09 82CR09 28CR09 04CR10 09CR10 10CR10 26CR10 70CR09 81CR09
2q 18,19 ++++
8p 18,19 ++
9p 19 ++ + + + +
9p21 18 ++ + +++
9q32-q34 19 +++ + +
doi:10.1371/journal.pone.0024237.t002
Figure 3. CNA collection evidenced by array-CGH. CNAs of 10 TCCs samples: 6 infiltrating tumors (IN-TCCs: 70CR09, 81CR09, 04CR10, 09CR10,
10CR10, 26CR10) on the left, and 4 non- infiltrating tumors (NI-TCCs: 28CR09, 75CR09, 80CR09, 82CR09) on the right. Each dot/bar corresponds to one
sample. Losses are evidenced in green while gains in red.
doi:10.1371/journal.pone.0024237.g003
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However, for the other tumors, a fairly good correlation has
been observed between the two techniques; ie for tumors
010CR10 and 070CR09 (both HGIN) the concordance was
evidenced for 3/4 targeted chromosomes. See Fig 5 for two
examples of more concordant (D) and less concordant (E) data.
The greater concordance was seen for chromosome 3 (7/10),
while the other targeted chromosomes showed a reasonable
correlation (6/10). For example, in 082CR09 (LGNI) and in
04CR10 (HGIN), 9p21 losses were evidenced only by FISH
analysis; on the other hand the amplification at locus 3p25 for
028CR09 (HGNI) and for 070CR09 (HGIN) emerged only from
array-CGH data. In order to validate array-CGH data and to
distinguish a polysomy of chromosome 3 from a true amplifi-
cation, FISH analysis was performed with both Urovysion test
assay and the dual-color split probe PPARc (3p25), on two
consecutive FFPE sections of 028CR09 (Figure 5, C). A statistical
analysis of signal counts on 100 nuclei assessed the true
amplification at 3p25 respect to a polysomy of chromosome 3
(tt e s t :p ,0.01).
Discussion
Despite the extensive research into genetic alterations of bladder
cancer and detailed models which link such changes to tumor
initiation and progression [20–22], there are few reliable markers
to distinguish tumors with aggressive characteristics at the time of
early diagnosis and we are still looking for the method of election
to detect them. In this regard, a recent prospective study has even
suggested that cystoscopy alone remains the most cost-effective
strategy for detecting recurrence of bladder cancer not invading
the muscle [28]. However, in contrast to what previously reported
by others [29], several authors claimed the same conclusion [30],
and the role of Urovysion in suspicious urine specimens remained
questionable, especially in view of its high cost.
The development of array-CGH led to the possibility to analyze
the whole genome in a single experiment, suggesting its possible
application in screening/surveillance programs of cancer patients.
In the case of bladder cancer, array-CGH would give the
possibility to analyze the DNA from a biopsy of the tumor, while
by Urovysion urine specimens are usually analyzed.
Figure 4. Examples of concordant and non-concordant results of Urovysion test. Comparison between results on two selected tumoral
areas of the same section of FFPE: (A): the two most concordant tumors (070CR09 and 081CR09); (B): the two most discordant tumors (009CR10 and
026CR10).
doi:10.1371/journal.pone.0024237.g004
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SAMPLE UROVYSION AREA 1 UROVYSION AREA 2 Array-CGH
LOSS% GAIN% LOSS% GAIN% LOSS% GAIN%
075CR09
LG NI
CR3* 12 29 na na - -
CR7** 2 24 na na - -
CR17* 25 12 na na - -
9p21** 46 5 na na mosaic 48% -
080CR09
LG NI
CR3** 4 27 4 16 - 3q25.2, 1.2 Mb, amplification 3q26.1,
1.8 Mb, non mosaic
C R 7 78 41 2- -
CR17** 25 3 10 8 17p13.3, 0.07 Mb, mosaic 87% -
9p21 100 0 100 0 non mosaic -
082CR09
LG NI
CR3* 1 29 na na - -
CR7** 0 14 na na - -
CR17** 7 7 na na - -
9p21* 93 1 na na - -
028CR09
HG NI
CR3 1 56 0 53 - 3p25.2-p25.1, 2 Mb, amplification
3p21.31, 3 Mb, mosaic 62% 3q11.2-q29,
99.5 Mb, mosaic 51%
CR7 3 57 0 33 7p22.3, 0.1 Mb, non mosaic 7p22.2-p22.1, 2 Mb, mosaic 80% 7p15.3,
0.3 Mb, mosaic 62% 7p14.2, 0.28 Mb, non
mosaic 7q11.21-q11.23, 1.2 Mb, mos 77%
7q21.3-q22.2, 7.6 Mb, mosaic 62%
7q32.1-q32.2, 1 Mb, mosaic 85% 7q33.34,
2.9 Mb, mosaic 77% 7q36.1, 0.7 Mb, non
mosaic
CR17 0 53 1 39 - 17q11.1-q25.3, 56 Mb, mosaic 85%
9p21 55 4 78 1 non mosaic -
004CR10
HG IN
CR3** 20 18 14 28 - 3q25.32-q26.1, 2.2 Mb, mos 51%
CR7* 8 12 4 24 - 7p21.1, 3.6 Mb, mos 68%
CR17* 28 4 18 21 - 17p11.2, 0.4 Mb, mosaic 48% 17q11.2,
2.9 Mb, mosaic 45% 17q12-q25.3, 49 Mb,
mosaic 39%
9p21** 70 0 28 13 - -
009CR10
HG IN
CR3 0 52 0 38 - 3p26.3-p11.1, 90 Mb, mosaic 75% 3q11.2-
q29, 104.2 Mb, mosaic 60%
CR7 0 56 0 44 - 7p22.3-p11.2, 56.2 Mb, mosaic 39%
7q11.21-q36.3, 96.3 Mb, mosaic 66%
CR17 0 49 0 38 17p13.3-p11.2, 21.8 Mb, mosaic 33% 17q11.1-q25.3, 55.8 Mb, mosaic 28%
9p21 76 1 96 0 mosaic 33% -
010CR10
HG IN
CR3 3 31 2 49 3p21.31-p12.1, 35.1 Mb, mosaic 28% 3p16.3-p24.3, 6.6 Mb, mosaic 68%
CR7** 0 33 1 31 7p21.1, 0.3 Mb, mosaic 91% -
CR17 10 25 9 25 - 17q11.1-q25.3, 55.7 Mb, mosaic 30%
9p21 91 1 99 0 non mosaic -
026CR10
HG IN
CR3** 0 38 0 39 3p21.31-p21.1, 4.2 Mb, mosaic 27% -
CR7* 1 15 0 34 - -
CR17* 7 19 0 25 - -
9p21 32 30 97 0 mosaic 68% -
070CR09
HG IN
CR3 0 52 0 38 - 3p25.2-p25.1, 0.7 Mb, amplification
Chromosomal Aberrations in Bladder Cancer
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specific and sensitive, it is invasive and still expensive.
Furthermore, to date there are no sufficient data to support the
use of array-CGH in this kind of programs, but it could be
interesting to apply this technique for patients’ categories with
high cancer risk.
The multitarget Urovysion assay has been developed for the
detection of TCC in urine specimens [7]. The optimal FISH probe
set was determined by testing different probes for TCC detection
in urine from patients with bladder cancer and selecting those that
were either the most sensitive individually or that complemented
other probes to enhance the overall sensitivity of the test. The CEP
probes and LSI 9p21 were complementary because the CEP
probes detect hyperdiploidy, common in carcinoma in situ and
invasive TCC, while the LSI 9p21 probe detects deletions of the
9p21 band, common in non-invasive TCC [7]. It has been
previously suggested that a false-negative FISH result represents
mostly low-grade TCC that do not shed tumor cells into the urine
or do not exhibit the chromosomal alterations that are detected by
the assay [11]. Another limit, and another possible explanation for
false-negative FISH results, might be attributed to the low number
of neoplastic cells present in the specimens [30].
In the first step of this study we compared the performance of
this multitarget assay for the detection of bladder tumor cells both
in FIN, without histological diagnosis and even with a low number
of neoplastic cells, and in FFPE tissue. Our analysis evidenced a
good correspondence of Urovysion FISH data between FIN and
FFPE for LGNI and HGIN tumors; in particular, in the former
group, FIN tended to detect a smaller number of signal respect to
FFPE, while in the latter group an opposite tendency was
appreciated. For HGNI TCCs, significant differences emerged
for three targeted probes, but it could be due to the low number of
samples of this group. The performance of this targeted test is
therefore sufficiently acceptable also on FIN samples; furthermore
the same CNAs were faithfully reflected by the analysis on FFPE.
It remains to investigate whether it is an efficient method to detect
the most representative and effective CNAs of TCCs. For this
purpose, in the second step of this study, array-CGH was
performed on 10 additional TCCs to dissect the spectrum of
alterations in bladder cancer and to identify recurrent aberrations
that may contain cancer-related genes.
We detected numerous genetic changes by array-CGH: the
most frequent loss involved chromosome 9p-arm while the most
frequent gain involved chromosome 20q-arm, as previously
reported by others [5,6,14,18,19]. Surprisingly, we didn’t find a
high percentage of tumors with gain of 6p22.3 and 8q reported in
other studies [14,18,19]. LOH and under-representation of
chromosome 9 is the most frequently described genetic alteration
in TCC (.50%). The common loss of an entire copy of
chromosome 9 indicates the presence of tumor suppressor genes
both on 9p and 9q, and candidate genes have been identified in
several regions including 9p21 (CDKN2A), 9q12-13 (PTCH), 9q32-
33 (DBC1) and 9q34 (TSC1). In this study, we observed complete
or partial loss of 9p and/or 9q in 7/10 tumors, in both HG and
LG. Moreover, in some HG we observed a gain for this locus, even
if this could be due to chromosome 9 polyploidy (as the sign of
chromosomal instability). The most frequent gain is 20q (6
tumors), in accordance with data previously reported in many
other cancers, including bladder, colon, ovarian and breast [31].
Association of 5p and 20q gains, found in 3 HG tumors, reported
by Bruch [32], could be associated with progression. Finally, gain
of 17q21 is identified only in HG tumors, suggesting a possible role
in tumor progression.
The most interesting point of this study is the comparison of
array-CGH data and Urovysion FISH data. Indeed, we
evidenced not only a high intra and inter-tumor heterogeneity
in FFPE material, as emerged from the analysis of two different
tumoral areas of the same tumor; we also found some
discrepancies in the two techniques that could be partially
ascribed to a possible masking effect from normal cells or to a
compensatory effect derived from the great tumor heterogeneity.
This heterogeneity has already been described by our group in
bladder cancer stem-like cells that are genetically different [33].
We can suggest that this diversity generates viable and clonally
related subpopulations that become heterogeneous in the same
tumor.
The overall array-CGH data stressed once again on the
presence of frequent alterations (i.e. 20p and 5p gains) that cannot
be detected by Urovysion assay. A further advantage of using an
integrated technical approach emerged for 028CR09 sample: the
amplification of 3p evidenced by array-CGH was studied by FISH
with Urovysion assay and a LSI 3p probe. Through the
SAMPLE UROVYSION AREA 1 UROVYSION AREA 2 Array-CGH
LOSS% GAIN% LOSS% GAIN% LOSS% GAIN%
CR7 0 44 0 58 - 7p22.3-q36.3, 158 Mb, mosaic 66%
CR17 10 50 6 44 17q11.2-q12, 1 Mb, mosaic 48% 17q21.31-q25.3, 40 Mb, mosaic 46%
9p21** 18 32 4 46 - -
081CR09
HG IN
CR3 0 58 0 41 - 3p25.2, 0.06 Mb, mosaic 62%
CR7** 0 52 2 25 - -
CR17** 1 47 12 25 - -
9p21** 11 42 13 33 - -
LOSS: number of signals: 0 and 1; DISOMY: number of signals even (2, 4, 6, 8, 10, 12); GAIN number of signals odd (3, 5, 7, 9, 11).
Gray: CNA detected by both techniques and by both tumoral FISH areas.
**: CNA detected by both techniques but by only one tumoral FISH area; or by both tumoral FISH area but not by array-CGH.
*: CNA detected by only array-CGH, or by only one tumoral FISH area.
Positive FISH if at least 25% of cells detected the CNA.
Na: not available.
doi:10.1371/journal.pone.0024237.t003
Table 3. Cont.
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true amplification from a chromosome 3 polysomy. This locus
includes the peroxisome proliferator-activated receptor gamma
(PPARG), a ligand activated transcription factor implicated in the
regulation of proliferation and differentiation of urothelium
[34,35].
In conclusion, considerable effort is still required to define the
genes underlying the chromosomal abnormalities to a better
understand of the genetic mechanisms in order to develop new
therapeutic strategies. Our results confirmed the importance of
global genomic screening methods, that is array based CGH, to
comprehensively determine the genomic profiles of large series of
TCCs tumors. However, this technique has yet some limitations,
such as not being able to detect low level mosaicism, or not
detecting any change in the number of copies for a kind of
compensatory effect due to the presence of high cellular
heterogeneity. Thus, it is still advisable to use complementary
techniques such array-CGH and FISH, as the former is able to
detect alterations at the genome level not excluding any
chromosome, but the latter is able to maintain the individual
data at the level of single cells, even if it focuses on few genomic
regions.
Figure 5. Examples of FISH analysis. Urovysion test applied to: (A): FIN sample 032CR07 (HG NI); (B): FFPE sample 080CR09 (LG NI). (C) FISH with
PPARc probe on 028CR09 (HGNI). Urovysion versus array-CGH data: example of concordant data (D), (sample 080CR09); and non-concordant data (E),
(sample 004CR10).
doi:10.1371/journal.pone.0024237.g005
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A detailed form can be found in Materials and Methods S1.
This study was approved and founded by Direzione Generale
Sanita ` Regione Lombardia and presented by General Director
and ethic commitment of ICP Hospital Bassini. Written informed
consent was obtained from the study participants before tissue
collection.
Patients and samples
A total of 32 tumor samples (28 men and 4 women) were
obtained by transurethral resection in a consecutive series of
patients newly diagnosed with TCCs at a single center (Table S1).
Informed consent was obtained before tissue collection. Staging
and grading were done according to the World Health
Organization Consensus Classification [1]. They were distin-
guished in high or low grade (HG or LG) and in muscle invasive or
not (IN or NI).
Fluorescence in situ hybridization
For FIN, biopsies were cut up and cultured in RPMI-1640
(Euroclone Spa) supplemented with 20% FCS for 24 hours. Pieces
were subjected to hypotonic treatment and fixed with 3:1
methanol:acetic acid. Single cells isolated from biopsies with
acetic acid 60%, were spotted on slides and let dry. For FFPE,
tissue were fixed according to standard procedures.
Pretreatment and FISH analysis were performed on both nuclei
isolated from FIN and FFPE samples using UroVysion bladder
cancer kit (Vysis, Wiesbaden, Germany), according to the
manufacturer’s instructions.
After hybridization the unbound probes were removed by a
series of washes and the nuclei were counterstained with 49,6-
diamidino-2-phenylindole (DAPI).
At least 100 cells for each preparation were scored and the
signals were divided according to loss (number of signals/cell ,2),
disomy (number of signals/cell =2) and gain (number of signals/
cell .2).
For locus 3p25 FISH analysis on FFPE was performed using
Poseidon
TM Repeat Free
TM PPARc (3p25) Break probe (Kreatech
Diagnostics, Amsterdam, Netherlands). The statistical significance of
differences between chromosome 3 polisomy and 3p25 amplification
was evaluated by Student’s t test on separate counts of 100 nuclei.
Differences were considered as statistically significant with p,0.01.
All digital images were captured using a Leitz microscope (Leica
DM 5000B) equipped with a charge coupled device (CCD) camera
and analyzed by means of Chromowin software (Tesi Imaging,
Milan, Italy).
Array-CGH
For array-CGH analysis, genomic DNA was extracted from fresh
biopsies after enzymatic digestion with collagenase H (Roche,
Mannheim, Germany) and proteinase K (Roche, Mannheim,
Germany) and purified using phenol/chloroform (Carlo Erba,
Milan, Italy). Sample preparation, slide hybridization, and analysis
were performed using SurePrint G3 Human CGH Microarray
8x60K (Agilent, Santa Clara, CA) according to the manufacturer’s
instructions. Sex-matched commercial DNA samples (Promega)
were used as reference DNA during array-CGH. The arrays were
scanned at 2-mm resolution using Agilent microarray scanner and
analyzed using Feature Extraction v10.7 and Agilent Genomic
Workbench v5.0 softwares. The Aberration Detection Method 2
(ADM2)algorithmpromptedbyGenomic Workbenchsoftware was
used to compute and assist the identification of aberrations for a
given sample (threshold=5; log2 ratio=0.3). To calculate the
estimated percentage of mosaicism we used the formula determined
by Cheung SW et al. [36].
Gene ontology analysis
To analyze which ontology classes were over- and under-
represented among the genes delineated within gain and loss
regions detected by array-CGH, the GOstat software (available at
http://gostat.wehi.edu.au/) was used [37] based on AmiGO (the
Gene Ontology database) version 1.8.
Statistical analysis
Cases were described by calculating the proportions of loss,
disomy and gain on the total of at least 100 cells, specifically for
type of analysis (FFPE and FIN), and probe of UroVysion test.
A multinomial model accounting for the presence of clustering
was used to estimate for each type of tumor and type of analysis,
the overall proportion of loss, disomy and gain with 95%
confidence intervals. This model was also used to compare the
overall proportions of loss, disomy and gain detected by the two
types of analysis.
A Poisson model based on logarithmic transformation of counts
in the presence of clustering was used to estimate the number of
signals detected by each type of analysis with 95% confidence
intervals. This model enabled also to compare the number of
signals across the two types of analysis (FFPE and FIN).
Supporting Information
Table S1 Clinicopathologic characteristics of 32 tumor
samples of the study. Histology/Grade and phase of study are
indicated.
(DOC)
Table S2 UroVysion test results on freshly isolated
interphasic nuclei (FIN) and on formalin fixed paraffin
embedded nuclei (FFPE).
(DOC)
Table S3 Copy number alterations (CNA) shared (plus
sign) among 10 TCC samples analyzed by array-CGH.
NI-TCCs are indicated in italics; IN-TCCs are indicated in bold.
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Table S4 Gene Ontology. I. Statistically significant (p,0.05)
under-representation of gene ontology (GO) categories in HG IN
tumors. II. Statistically significant (p,0.05) over-representation of
gene ontology (GO) categories in HG IN tumors. III. Statistically
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categories in LG NI tumors.
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areas of the same section
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